Miami-based TissueTech, a biotech company that focuses on regenerative medicine, raised $15 million in venture funding.
Ballast Point Ventures of St. Petersburg and River Cities Capital Funds in Raleigh led a Series B equity raise for TissueTech, a regenerative medicine company in Miami.
TissueTech, now with more than 100 employees, develops regenerative amniotic tissue-based products for the ophthalmology, optometry, musculoskeletal and wound care markets. The company will use the funding to expand sales and marketing and research and development.
Ballast Point and River Cities invested $10 million in TissueTech in 2013.